<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318149</url>
  </required_header>
  <id_info>
    <org_study_id>104886</org_study_id>
    <nct_id>NCT00318149</nct_id>
  </id_info>
  <brief_title>Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population</brief_title>
  <official_title>Demonstrate the Non-inferiority in Term of Cellular Mediated Immune Response of GSK Biologicals' Influenza Candidate Vaccines Containing Various Adjuvants Administered in Elderly Population (Aged 65 Years &amp;Amp; Older) vs Fluarix™ (Known as Alpha-Rix™ in Belgium) Administered in Adults (18-40 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy
      adults, probably as a result of immunosenescence, there is a desire to devise ways to
      increase the current vaccines efficacy for this target population. Adjuvants are known to
      boost immune responses, thus representing one way to increase the efficacy of the current
      GlaxoSmithKline Fluarix™ influenza vaccine in elderly subjects. The purpose of this study is
      to evaluate the immunogenicity and the reactogenicity of a vaccination with four different
      adjuvanted GlaxoSmithKline influenza vaccines administered to elderly subjects. For
      immunogenicity and safety evaluations, healthy adults aged 18 to 40 years old and elderly
      aged 65 years and older will receive Fluarix™ and form the control groups of this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2005</start_date>
  <completion_date type="Actual">May 14, 2006</completion_date>
  <primary_completion_date type="Actual">May 14, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Influenza-specific Cluster of Differentiation 4+ (CD4+) T-cells Expressing at Least 2 Markers</measure>
    <time_frame>At Day 21</time_frame>
    <description>The frequency was expressed as the geometric mean of influenza-specific CD4 T-cells, expressing at least 2 markers among CD40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α) and Interferon-γ (IFN-γ ) upon in vitro stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 and at Day 21</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).
Seropositivity was defined as a serum HI titer greater than or equal to (≥) 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum HI Antibodies Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 90 and Day 180</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).
Seropositivity was defined as a serum HI titer of ≥ 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 90 and Day 180</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 21</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold change in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to pre-vaccination time point. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 90 and Day 180</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold change in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to pre-vaccination time point. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 and at Day 21</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease</measure>
    <time_frame>At Day 90 and Day 180</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited local symptoms were haematoma, pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevented normal everyday activity. Grade 3 haematoma/redness/swelling = haematoma/redness/swelling spreading beyond 50 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], headache, joint pain, muscle aches and shivering. Any = occurrence of any general symptom regardless of intensity grade and relationship to vaccination. Grade 3 = symptoms that prevented normal activity. Grade 3 fever = fever &gt;39°C. Related = general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 21-day (Days 0-20) follow-up period after vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 =event that prevented normal everyday activity. Related = event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluarix 18-40 Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix ≥65 Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix-AS25 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix-AS50 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix- AS01B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix- AS01E Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>1 dose administered intramuscularly in the deltoid region of the non-dominant arm</description>
    <arm_group_label>Fluarix 18-40 Y Group</arm_group_label>
    <arm_group_label>Fluarix ≥65 Y Group</arm_group_label>
    <other_name>GlaxoSmithKline Biologicals` licensed influenza vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix-AS25</intervention_name>
    <description>1 dose administered intramuscularly into the deltoid region of the non-dominant arm</description>
    <arm_group_label>Fluarix-AS25 Group</arm_group_label>
    <other_name>Fluarix vaccine adjuvanted with AS25</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix-AS50</intervention_name>
    <description>1 dose administered intramuscularly into the deltoid region of the non-dominant arm</description>
    <arm_group_label>Fluarix-AS50 Group</arm_group_label>
    <other_name>Fluarix vaccine adjuvanted with AS25</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix-AS01B</intervention_name>
    <description>1 dose administered intramuscularly into the deltoid region of the non-dominant arm</description>
    <arm_group_label>Fluarix- AS01B Group</arm_group_label>
    <other_name>Fluarix vaccine adjuvanted with AS01B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix-AS01E</intervention_name>
    <description>1 dose administered intramuscularly into the deltoid region of the non-dominant arm</description>
    <arm_group_label>Fluarix- AS01E Group</arm_group_label>
    <other_name>Fluarix vaccine adjuvanted with AS01E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female aged between 18 and 40 years or aged 65 years or older at the time of
             the vaccination.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the administration of the study vaccine, or
             planned use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the administration of the study
             vaccine.

          -  History of confirmed influenza infection since a year from the date of previous
             vaccination.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  History of hypersensitivity to vaccines.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, as determined by physical examination or laboratory screening tests.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the administration of the study vaccine or during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <results_first_submitted>January 27, 2017</results_first_submitted>
  <results_first_submitted_qc>February 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104886</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104886</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104886</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104886</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104886</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104886</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluarix 18-40 Y Group</title>
          <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix ≥65 Y Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Fluarix-AS25 Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Fluarix-AS50 Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>Fluarix- AS01B Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P6">
          <title>Fluarix- AS01E Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluarix 18-40 Y Group</title>
          <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix ≥65 Y Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix-AS25 Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Fluarix-AS50 Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Fluarix- AS01B Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>Fluarix- AS01E Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="75"/>
            <count group_id="B6" value="75"/>
            <count group_id="B7" value="425"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="5.47"/>
                    <measurement group_id="B2" value="69.3" spread="3.31"/>
                    <measurement group_id="B3" value="69.2" spread="2.98"/>
                    <measurement group_id="B4" value="69.1" spread="3.51"/>
                    <measurement group_id="B5" value="69.5" spread="3.3"/>
                    <measurement group_id="B6" value="69.5" spread="4.06"/>
                    <measurement group_id="B7" value="61.66" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Geographic ancestry</title>
              <category_list>
                <category>
                  <title>Asian - Central/South Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Caucasian/European heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="75"/>
                    <measurement group_id="B7" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Influenza-specific Cluster of Differentiation 4+ (CD4+) T-cells Expressing at Least 2 Markers</title>
        <description>The frequency was expressed as the geometric mean of influenza-specific CD4 T-cells, expressing at least 2 markers among CD40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α) and Interferon-γ (IFN-γ ) upon in vitro stimulation.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Influenza-specific Cluster of Differentiation 4+ (CD4+) T-cells Expressing at Least 2 Markers</title>
          <description>The frequency was expressed as the geometric mean of influenza-specific CD4 T-cells, expressing at least 2 markers among CD40 Ligand (CD40L), Interleukin 2 (IL-2), Tumor Necrosis Factor-α (TNF-α) and Interferon-γ (IFN-γ ) upon in vitro stimulation.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
          <units>T-cells/million cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3229.25" spread="1643.2"/>
                    <measurement group_id="O2" value="1646.05" spread="1557.22"/>
                    <measurement group_id="O3" value="3056.06" spread="2059.35"/>
                    <measurement group_id="O4" value="2589.31" spread="2110.15"/>
                    <measurement group_id="O5" value="2454.93" spread="1758.20"/>
                    <measurement group_id="O6" value="2428.78" spread="2693.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Demonstration of non inferiority of the influenza adjuvanted vaccine Fluarix-AS25 administered to elderly subjects (aged 65 years and older) as compared to the licensed influenza vaccine Fluarix administered to adults (aged 18-40 years) in terms of frequency of influenza-specific CD4 T-cells producing at least 2 different cytokines (CD40L, IL-2, TNF-α or IFN-γ), 21 days post-vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non inferiority criteria: The upper limit (UL) of the 2-sided 98.75% confidence interval (CI) on geometric mean ratio of influenza-specific T-cells (between Fluarix 18-40 Y Group and Fluarix-AS25 Group) was smaller than (&lt;) 2.0.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Demonstration of non inferiority of the influenza adjuvanted vaccine Fluarix-AS50 administered to elderly subjects (aged 65 years and older) as compared to the licensed influenza vaccine Fluarix administered to adults (aged 18-40 years) in terms of frequency of influenza-specific CD4 T-cells producing at least 2 different cytokines (CD40L, IL-2, TNF-α or IFN-γ), 21 days post-vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non inferiority criteria: The upper limit (UL) of the 2-sided 98.75% confidence interval (CI) on geometric mean ratio of influenza-specific T-cells (between Fluarix 18-40 Y Group and Fluarix-AS50 Group) was smaller than (&lt;) 2.0.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Demonstration of non inferiority of the influenza adjuvanted vaccine Fluarix-AS01B administered to elderly subjects (aged 65 years and older) as compared to the licensed influenza vaccine Fluarix administered to adults (aged 18-40 years) in terms of frequency of influenza-specific CD4 T-cells producing at least 2 different cytokines (CD40L, IL-2, TNF-α or IFN-γ), 21 days post-vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non inferiority criteria: The upper limit (UL) of the 2-sided 98.75% confidence interval (CI) on geometric mean ratio of influenza-specific T-cells (between Fluarix 18-40 Y Group and Fluarix-AS01B Group) was smaller than (&lt;) 2.0.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Demonstration of non inferiority of the influenza adjuvanted vaccine Fluarix-AS01E administered to elderly subjects (aged 65 years and older) as compared to the licensed influenza vaccine Fluarix administered to adults (aged 18-40 years) in terms of frequency of influenza-specific CD4 T-cells producing at least 2 different cytokines (CD40L, IL-2, TNF-α or IFN-γ), 21 days post-vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non inferiority criteria: The upper limit (UL) of the 2-sided 98.75% confidence interval (CI) on geometric mean ratio of influenza-specific T-cells (between Fluarix 18-40 Y Group and Fluarix-AS01E Group) was smaller than (&lt;) 2.0.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).
Seropositivity was defined as a serum HI titer greater than or equal to (≥) 1:10.</description>
        <time_frame>At Day 0 and at Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).
Seropositivity was defined as a serum HI titer greater than or equal to (≥) 1:10.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="14.3" upper_limit="30.2"/>
                    <measurement group_id="O2" value="23.5" lower_limit="16.2" upper_limit="34.1"/>
                    <measurement group_id="O3" value="23.9" lower_limit="17.6" upper_limit="32.5"/>
                    <measurement group_id="O4" value="24.1" lower_limit="18.1" upper_limit="32.3"/>
                    <measurement group_id="O5" value="33.9" lower_limit="24.5" upper_limit="46.9"/>
                    <measurement group_id="O6" value="33.5" lower_limit="24.5" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="728.4" lower_limit="549.2" upper_limit="966.0"/>
                    <measurement group_id="O2" value="86.5" lower_limit="58.7" upper_limit="127.4"/>
                    <measurement group_id="O3" value="151.9" lower_limit="115.1" upper_limit="200.5"/>
                    <measurement group_id="O4" value="223.2" lower_limit="170.5" upper_limit="292.3"/>
                    <measurement group_id="O5" value="151.4" lower_limit="118.4" upper_limit="193.6"/>
                    <measurement group_id="O6" value="166.8" lower_limit="130.1" upper_limit="213.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.8" upper_limit="21.4"/>
                    <measurement group_id="O2" value="12.0" lower_limit="9.2" upper_limit="15.6"/>
                    <measurement group_id="O3" value="13.0" lower_limit="10.1" upper_limit="16.7"/>
                    <measurement group_id="O4" value="16.0" lower_limit="12.1" upper_limit="21.2"/>
                    <measurement group_id="O5" value="15.5" lower_limit="12.3" upper_limit="19.6"/>
                    <measurement group_id="O6" value="17.2" lower_limit="12.9" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.3" lower_limit="119.8" upper_limit="191.1"/>
                    <measurement group_id="O2" value="98.9" lower_limit="65.1" upper_limit="150.3"/>
                    <measurement group_id="O3" value="249.7" lower_limit="186.2" upper_limit="334.8"/>
                    <measurement group_id="O4" value="240.3" lower_limit="176.0" upper_limit="328.0"/>
                    <measurement group_id="O5" value="202.5" lower_limit="157.6" upper_limit="260.2"/>
                    <measurement group_id="O6" value="249.3" lower_limit="181.7" upper_limit="342.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" lower_limit="18.9" upper_limit="33.6"/>
                    <measurement group_id="O2" value="31.4" lower_limit="21.8" upper_limit="45.2"/>
                    <measurement group_id="O3" value="27.7" lower_limit="21.1" upper_limit="36.5"/>
                    <measurement group_id="O4" value="38.7" lower_limit="27.7" upper_limit="54.0"/>
                    <measurement group_id="O5" value="39.2" lower_limit="30.2" upper_limit="51.0"/>
                    <measurement group_id="O6" value="30.0" lower_limit="23.2" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.5" lower_limit="270.7" upper_limit="451.2"/>
                    <measurement group_id="O2" value="134.1" lower_limit="100.2" upper_limit="179.4"/>
                    <measurement group_id="O3" value="237.1" lower_limit="185.1" upper_limit="303.8"/>
                    <measurement group_id="O4" value="293.1" lower_limit="234.1" upper_limit="366.8"/>
                    <measurement group_id="O5" value="205.4" lower_limit="171.3" upper_limit="246.2"/>
                    <measurement group_id="O6" value="202.6" lower_limit="161.2" upper_limit="254.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum HI Antibodies Against 3 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).
Seropositivity was defined as a serum HI titer of ≥ 1:10.</description>
        <time_frame>At Day 90 and Day 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum HI Antibodies Against 3 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).
Seropositivity was defined as a serum HI titer of ≥ 1:10.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496.4" lower_limit="370.1" upper_limit="665.7"/>
                    <measurement group_id="O2" value="76.7" lower_limit="54.1" upper_limit="108.8"/>
                    <measurement group_id="O3" value="94.2" lower_limit="74.7" upper_limit="118.8"/>
                    <measurement group_id="O4" value="135.3" lower_limit="102.4" upper_limit="178.7"/>
                    <measurement group_id="O5" value="97.4" lower_limit="78.1" upper_limit="121.4"/>
                    <measurement group_id="O6" value="105.9" lower_limit="84.3" upper_limit="133.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.7" lower_limit="260.3" upper_limit="483.5"/>
                    <measurement group_id="O2" value="62.9" lower_limit="45.4" upper_limit="87.1"/>
                    <measurement group_id="O3" value="66.9" lower_limit="53.3" upper_limit="84.1"/>
                    <measurement group_id="O4" value="89.1" lower_limit="67.2" upper_limit="118.2"/>
                    <measurement group_id="O5" value="70.5" lower_limit="56.5" upper_limit="87.9"/>
                    <measurement group_id="O6" value="81.9" lower_limit="65.1" upper_limit="103.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.5" lower_limit="100.8" upper_limit="168.9"/>
                    <measurement group_id="O2" value="60.7" lower_limit="41.4" upper_limit="89.1"/>
                    <measurement group_id="O3" value="99.2" lower_limit="75.2" upper_limit="131.0"/>
                    <measurement group_id="O4" value="116.4" lower_limit="88.6" upper_limit="153.0"/>
                    <measurement group_id="O5" value="93.3" lower_limit="73.2" upper_limit="119.0"/>
                    <measurement group_id="O6" value="114.8" lower_limit="85.1" upper_limit="154.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="73.5" upper_limit="126.6"/>
                    <measurement group_id="O2" value="43.8" lower_limit="30.2" upper_limit="63.7"/>
                    <measurement group_id="O3" value="66.3" lower_limit="50.5" upper_limit="87.1"/>
                    <measurement group_id="O4" value="71.8" lower_limit="55.6" upper_limit="92.7"/>
                    <measurement group_id="O5" value="59.5" lower_limit="46.8" upper_limit="75.6"/>
                    <measurement group_id="O6" value="70.4" lower_limit="53.0" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.2" lower_limit="161.0" upper_limit="269.3"/>
                    <measurement group_id="O2" value="131.3" lower_limit="98.1" upper_limit="175.8"/>
                    <measurement group_id="O3" value="145.6" lower_limit="110.7" upper_limit="191.6"/>
                    <measurement group_id="O4" value="213.0" lower_limit="173.0" upper_limit="262.1"/>
                    <measurement group_id="O5" value="147.1" lower_limit="120.7" upper_limit="179.2"/>
                    <measurement group_id="O6" value="144.2" lower_limit="116.6" upper_limit="178.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.3" lower_limit="109.0" upper_limit="180.5"/>
                    <measurement group_id="O2" value="94.5" lower_limit="69.2" upper_limit="129.0"/>
                    <measurement group_id="O3" value="91.6" lower_limit="71.4" upper_limit="117.6"/>
                    <measurement group_id="O4" value="128.0" lower_limit="102.6" upper_limit="159.8"/>
                    <measurement group_id="O5" value="111.0" lower_limit="88.3" upper_limit="139.6"/>
                    <measurement group_id="O6" value="91.4" lower_limit="74.3" upper_limit="112.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia (H1N1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu (B).</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
        <time_frame>At Day 90 and Day 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</title>
        <description>The seroconversion factor (SCF) was defined as the fold change in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to pre-vaccination time point. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</title>
          <description>The seroconversion factor (SCF) was defined as the fold change in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to pre-vaccination time point. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="21.9" upper_limit="56.4"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.4" upper_limit="5.7"/>
                    <measurement group_id="O3" value="6.4" lower_limit="4.5" upper_limit="9.0"/>
                    <measurement group_id="O4" value="9.2" lower_limit="6.4" upper_limit="13.3"/>
                    <measurement group_id="O5" value="4.5" lower_limit="3.3" upper_limit="6.1"/>
                    <measurement group_id="O6" value="5.0" lower_limit="3.6" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="7.1" upper_limit="11.8"/>
                    <measurement group_id="O2" value="8.2" lower_limit="5.7" upper_limit="11.8"/>
                    <measurement group_id="O3" value="19.2" lower_limit="14.6" upper_limit="25.3"/>
                    <measurement group_id="O4" value="15.0" lower_limit="11.2" upper_limit="20.2"/>
                    <measurement group_id="O5" value="13.1" lower_limit="10.0" upper_limit="17.1"/>
                    <measurement group_id="O6" value="14.5" lower_limit="10.4" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="10.1" upper_limit="19.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.0" upper_limit="6.1"/>
                    <measurement group_id="O3" value="8.5" lower_limit="6.5" upper_limit="11.2"/>
                    <measurement group_id="O4" value="7.6" lower_limit="5.6" upper_limit="10.2"/>
                    <measurement group_id="O5" value="5.2" lower_limit="4.2" upper_limit="6.5"/>
                    <measurement group_id="O6" value="6.7" lower_limit="5.1" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</title>
        <description>The seroconversion factor (SCF) was defined as the fold change in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to pre-vaccination time point. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
        <time_frame>At Day 90 and Day 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease</title>
          <description>The seroconversion factor (SCF) was defined as the fold change in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to pre-vaccination time point. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
          <units>Fold change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="15.6" upper_limit="36.8"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.3" upper_limit="4.7"/>
                    <measurement group_id="O3" value="3.9" lower_limit="3.0" upper_limit="5.2"/>
                    <measurement group_id="O4" value="5.7" lower_limit="4.0" upper_limit="8.1"/>
                    <measurement group_id="O5" value="2.9" lower_limit="2.2" upper_limit="3.9"/>
                    <measurement group_id="O6" value="3.1" lower_limit="2.3" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="11.2" upper_limit="26.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.9" upper_limit="3.7"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.2" upper_limit="3.6"/>
                    <measurement group_id="O4" value="3.7" lower_limit="2.6" upper_limit="5.4"/>
                    <measurement group_id="O5" value="2.1" lower_limit="1.6" upper_limit="2.8"/>
                    <measurement group_id="O6" value="2.4" lower_limit="1.8" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.3" upper_limit="10.0"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.7" upper_limit="7"/>
                    <measurement group_id="O3" value="7.6" lower_limit="6.1" upper_limit="9.6"/>
                    <measurement group_id="O4" value="7.3" lower_limit="5.7" upper_limit="9.2"/>
                    <measurement group_id="O5" value="6.2" lower_limit="4.8" upper_limit="7.9"/>
                    <measurement group_id="O6" value="6.6" lower_limit="5.0" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="4.7" upper_limit="7.3"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.7" upper_limit="4.9"/>
                    <measurement group_id="O3" value="5.1" lower_limit="4.2" upper_limit="6.3"/>
                    <measurement group_id="O4" value="4.5" lower_limit="3.5" upper_limit="5.8"/>
                    <measurement group_id="O5" value="3.9" lower_limit="3.1" upper_limit="5.0"/>
                    <measurement group_id="O6" value="4.1" lower_limit="3.2" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="6.2" upper_limit="11.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3" upper_limit="5.9"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.2" upper_limit="6.6"/>
                    <measurement group_id="O4" value="5.6" lower_limit="4.3" upper_limit="7.2"/>
                    <measurement group_id="O5" value="3.7" lower_limit="3" upper_limit="4.6"/>
                    <measurement group_id="O6" value="4.8" lower_limit="3.7" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.3" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3" lower_limit="2.2" upper_limit="4.1"/>
                    <measurement group_id="O3" value="3.3" lower_limit="2.6" upper_limit="4.1"/>
                    <measurement group_id="O4" value="3.3" lower_limit="2.6" upper_limit="4.3"/>
                    <measurement group_id="O5" value="2.8" lower_limit="2.2" upper_limit="3.6"/>
                    <measurement group_id="O6" value="3.1" lower_limit="2.5" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
        <time_frame>At Day 0 and at Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity measures were available (subjects for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
        <time_frame>At Day 90 and Day 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The 3 flu strains assessed were A/New Caledonia (H1N1), A/New York (H3N2) and B/Jiangsu (B).</description>
          <population>The analysis was performed on the According-To-Protocol cohort for persistence included all subjects from the ATP cohort for immunogenicity who had not received any medication or vaccine forbidden by the protocol during the study period and who had available assay results for at least 1 tested antigen at the Day 90 or Day 180 time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Jiangsu, Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="74"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were haematoma, pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevented normal everyday activity. Grade 3 haematoma/redness/swelling = haematoma/redness/swelling spreading beyond 50 millimeters (mm).</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were haematoma, pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = pain which prevented normal everyday activity. Grade 3 haematoma/redness/swelling = haematoma/redness/swelling spreading beyond 50 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematoma, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematoma, &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], headache, joint pain, muscle aches and shivering. Any = occurrence of any general symptom regardless of intensity grade and relationship to vaccination. Grade 3 = symptoms that prevented normal activity. Grade 3 fever = fever &gt;39°C. Related = general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix-AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix-AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
          <description>Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], headache, joint pain, muscle aches and shivering. Any = occurrence of any general symptom regardless of intensity grade and relationship to vaccination. Grade 3 = symptoms that prevented normal activity. Grade 3 fever = fever &gt;39°C. Related = general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (axillary), Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (axillary), Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (axillary), Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering, Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 =event that prevented normal everyday activity. Related = event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 21-day (Days 0-20) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix- AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix- AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 =event that prevented normal everyday activity. Related = event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix 18-40 Y Group</title>
            <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix ≥65 Y Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix-AS25 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix-AS50 Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix-AS01B Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Fluarix-AS01E Group</title>
            <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects who received the vaccine dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited AEs: during the 21-day (Days 0-20) post-vaccination period; SAEs: during the entire study period (Days 0-180).</time_frame>
      <desc>For the solicited local and general symptoms occurring during the 7-day (Days 0-6) post-vaccination period, please refer to outcome measures 10 and 11 from the Outcome Measures section above.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluarix 18-40 Y Group</title>
          <description>Subjects (aged 18-40 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix ≥65 Y Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix-AS25 Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Fluarix-AS50 Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Fluarix- AS01B Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E6">
          <title>Fluarix- AS01E Group</title>
          <description>Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Campylobacter infeection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Scrotal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

